Balancing benefits and risks in the era of biologics

Giovanni Adami*, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guanabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet Geusens

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article numberUNSP 1759720X19883973
Number of pages6
JournalTherapeutic Advances in Musculoskeletal Disease
Volume11
DOIs
Publication statusPublished - Oct 2019

Keywords

  • benefit-risk ratio
  • biologics
  • denosumab
  • romosozumab
  • POSTMENOPAUSAL WOMEN
  • RHEUMATOID-ARTHRITIS
  • CERTOLIZUMAB PEGOL
  • ROMOSOZUMAB
  • PREVENTION
  • INFLIXIMAB
  • FRACTURES
  • DENOSUMAB
  • DISEASES
  • SAFETY

Cite this

Adami, G., Saag, K. G., Chapurlat, R. D., Guanabens, N., Haugeberg, G., Lems, W. F., ... Geusens, P. (2019). Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 11, [UNSP 1759720X19883973]. https://doi.org/10.1177/1759720X19883973
Adami, Giovanni ; Saag, Kenneth G. ; Chapurlat, Roland D. ; Guanabens, Nuria ; Haugeberg, Glenn ; Lems, Willem F. ; Matijevic, Radmila ; Peel, Nicola ; Poddubnyy, Denis ; Geusens, Piet. / Balancing benefits and risks in the era of biologics. In: Therapeutic Advances in Musculoskeletal Disease. 2019 ; Vol. 11.
@article{a27a76f2d6754c708609973c227600b8,
title = "Balancing benefits and risks in the era of biologics",
keywords = "benefit-risk ratio, biologics, denosumab, romosozumab, POSTMENOPAUSAL WOMEN, RHEUMATOID-ARTHRITIS, CERTOLIZUMAB PEGOL, ROMOSOZUMAB, PREVENTION, INFLIXIMAB, FRACTURES, DENOSUMAB, DISEASES, SAFETY",
author = "Giovanni Adami and Saag, {Kenneth G.} and Chapurlat, {Roland D.} and Nuria Guanabens and Glenn Haugeberg and Lems, {Willem F.} and Radmila Matijevic and Nicola Peel and Denis Poddubnyy and Piet Geusens",
year = "2019",
month = "10",
doi = "10.1177/1759720X19883973",
language = "English",
volume = "11",
journal = "Therapeutic Advances in Musculoskeletal Disease",
issn = "1759-720X",
publisher = "SAGE Publications Ltd",

}

Adami, G, Saag, KG, Chapurlat, RD, Guanabens, N, Haugeberg, G, Lems, WF, Matijevic, R, Peel, N, Poddubnyy, D & Geusens, P 2019, 'Balancing benefits and risks in the era of biologics', Therapeutic Advances in Musculoskeletal Disease, vol. 11, UNSP 1759720X19883973. https://doi.org/10.1177/1759720X19883973

Balancing benefits and risks in the era of biologics. / Adami, Giovanni; Saag, Kenneth G.; Chapurlat, Roland D.; Guanabens, Nuria; Haugeberg, Glenn; Lems, Willem F.; Matijevic, Radmila; Peel, Nicola; Poddubnyy, Denis; Geusens, Piet.

In: Therapeutic Advances in Musculoskeletal Disease, Vol. 11, UNSP 1759720X19883973, 10.2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Balancing benefits and risks in the era of biologics

AU - Adami, Giovanni

AU - Saag, Kenneth G.

AU - Chapurlat, Roland D.

AU - Guanabens, Nuria

AU - Haugeberg, Glenn

AU - Lems, Willem F.

AU - Matijevic, Radmila

AU - Peel, Nicola

AU - Poddubnyy, Denis

AU - Geusens, Piet

PY - 2019/10

Y1 - 2019/10

KW - benefit-risk ratio

KW - biologics

KW - denosumab

KW - romosozumab

KW - POSTMENOPAUSAL WOMEN

KW - RHEUMATOID-ARTHRITIS

KW - CERTOLIZUMAB PEGOL

KW - ROMOSOZUMAB

KW - PREVENTION

KW - INFLIXIMAB

KW - FRACTURES

KW - DENOSUMAB

KW - DISEASES

KW - SAFETY

U2 - 10.1177/1759720X19883973

DO - 10.1177/1759720X19883973

M3 - Review article

VL - 11

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

SN - 1759-720X

M1 - UNSP 1759720X19883973

ER -

Adami G, Saag KG, Chapurlat RD, Guanabens N, Haugeberg G, Lems WF et al. Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease. 2019 Oct;11. UNSP 1759720X19883973. https://doi.org/10.1177/1759720X19883973